Controversies surrounding iron chelation therapy for MDS.
Leitch
Heather A
HA
Division of Hematology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada. hleitch@providencehematology.com
D015913:Chelation Therapy / Q000009:adverse effects / Q000379:methods / Q000592:standards*; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D019190:Iron Overload / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000378:metabolism
D007502:Iron Chelating Agents